The investigators propose to conduct an open study to evaluate the efficacy and tolerability of Bupropion SR using clinically relevant doses in ADHD adults with a recent history of or current substance use disorders. We hypothesize that Bupropion SR will be effective in treating ADHD in this population.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
32
100mg capsules Initial dosing 100mgSR every morning, to be titrated to 200mgSR twice daily maximum
Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) Score
Assesses 18 individual criteria symptoms using a severity grid (0 = not present, 3 = severe; overall minimum score = 0, maximum score = 54)
Time frame: baseline and six weeks
Self-reported Weekly Substance Use
Number of subjects who self-report using at least one of illegal drugs or alcohol, at least once in a week.
Time frame: baseline and six weeks
Clinical Global Impressions (CGI) Scale of Substance Use Disorder (SUD) Severity
CGI-S 1=not ill, 7=extremely ill
Time frame: baseline and six weeks
Clinical Global Impressions (CGI) Scale of ADHD Severity
Global Severity (CGI-S) 1=not ill, 7=extremely ill
Time frame: baseline and six weeks
Hamilton Anxiety Scale (HAM-A)
minimum score (least severe anxiety) = 0, maximum (most severe) = 56
Time frame: baseline and six weeks
Hamilton Depression Scale (HAM-D)
minimum score (least severe depression) = 0, maximum score (most severe) = 84
Time frame: baseline and six weeks
Beck Depression Inventory (BDI)
minimum score (least severe depression) = 0, maximum score (most severe) = 63
Time frame: baseline and six weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.